WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 202260
CAS#: 155148-31-5 (HCl)
Description: Plerixafor, also known as AMD3100, is a bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). Plerixafor was approved by the U.S. Food and Drug Administration for this indication on December 15, 2008. In Europe, the drug was approved on 29 May 2009.
MedKoo Cat#: 202260
Name: Plerixafor HCl
CAS#: 155148-31-5 (HCl)
Chemical Formula: C28H62Cl8N8
Exact Mass:
Molecular Weight: 794.46
Elemental Analysis: C, 42.33; H, 7.87; Cl, 35.70; N, 14.10
Plerixafor HCl, purity > 98%, is in stock. The same day shipping after order is received.
Related CAS #: 155148-31-5 (HCl) 110078-46-1 (free base)
Synonym: AMD3100; AMD-3100; AMD 3100; JM 3100; JM3100; JM-3100; SDZ-SID-791; JLK-169; SID-791; JM-2987; Plerixafor HCl; MOZOBIL.
IUPAC/Chemical Name: 1,4-bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene octahydrochloride
InChi Key: UEUPDYPUTTUXLJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C28H54N8.8ClH/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H
SMILES Code: [H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.C1(CN2CCNCCCNCCNCCC2)=CC=C(CN3CCNCCCNCCNCCC3)C=C1
The following data is based on the product molecular weight 794.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Fricker SP. Physiology and Pharmacology of Plerixafor. Transfus Med Hemother. 2013 Aug;40(4):237-245. Epub 2013 Jul 19. Review. PubMed PMID: 24179472; PubMed Central PMCID: PMC3776399.
2: Pierelli L, Perseghin P. Plerixafor (Mozobil) and other mobilizing agents. Transfus Apher Sci. 2013 Apr;48(2):133-5. doi: 10.1016/j.transci.2013.02.005. Epub 2013 Apr 9. Review. PubMed PMID: 23582743.
3: Tanhehco YC, Vogl DT, Stadtmauer EA, O'Doherty U. The evolving role of plerixafor in hematopoietic progenitor cell mobilization. Transfusion. 2013 Oct;53(10):2314-26. doi: 10.1111/trf.12102. Epub 2013 Jan 30. Review. PubMed PMID: 23362980.
4: Gardellini A, Babic A, Gigli F, Liptrott SJ, Martinelli G, Laszlo D. Successful mobilisation of peripheral blood stem cells in children using plerixafor: a case report and review of the literature. Blood Transfus. 2013 Apr;11(2):308-10. doi: 10.2450/2012.0052-12. Epub 2012 Oct 10. Review. PubMed PMID: 23114521; PubMed Central PMCID: PMC3626485.
5: Dunn D, Vikas P, Jagasia M, Savani BN. Plerixafor in AL amyloidosis: improved graft composition and faster lymphocyte recovery after auto-SCT in patient with end-stage renal-disease. Bone Marrow Transplant. 2012 Aug;47(8):1136-7. doi: 10.1038/bmt.2011.226. Epub 2011 Nov 14. Review. PubMed PMID: 22080973.
6: Jantunen E, Lemoli RM. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion. 2012 Apr;52(4):906-14. doi: 10.1111/j.1537-2995.2011.03349.x. Epub 2011 Oct 7. Review. PubMed PMID: 21981351.
7: Keating GM. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. 2011 Aug 20;71(12):1623-47. doi: 10.2165/11206040-000000000-00000. Review. PubMed PMID: 21861545.
8: Jantunen E. Novel strategies for blood stem cell mobilization: special focus on plerixafor. Expert Opin Biol Ther. 2011 Sep;11(9):1241-8. doi: 10.1517/14712598.2011.601737. Review. PubMed PMID: 21806478.
9: Mohty M, Duarte RF, Croockewit S, Hübel K, Kvalheim G, Russell N. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia. 2011 Jan;25(1):1-6. doi: 10.1038/leu.2010.224. Review. PubMed PMID: 21224858.
10: Pelus LM, Farag SS. Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma. Stem Cells Cloning. 2011 Feb 27;4:11-22. doi: 10.2147/SCCAA.S6713. Review. PubMed PMID: 24198526; PubMed Central PMCID: PMC3781755.
Related CAS#
155148-31-5 ( Plerixafor HCl);
110078-46-1 ( Plerixafor Free base)
